Cellectis has entered into a new agreement with CELLforCURE for the cGMP manufacture of UCART123 clinical batches, Cellectis’ lead engineered T-cell product candidate. This agreement follows the recent successful production of UCART19. CELLforCURE, the largest industrial facility for clinical and commercial production of cell therapies in Europe, will implement cGMP manufacturing processes designed and developed by Cellectis. UCART123 targets CD123, an antigen expressed on the surface of can...